Sage Therapeutics Stock News

Style Box ETF report for EES

Over the past 3 months, 4 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding

Sage Therapeutics, Inc. (NASDAQ: SAGE) Q4 2021 earnings call dated Feb. 24, 2022 Corporate Participants: Helen Rubinstein — Investor Relations Officer Barry Greene — Chief Executive Officer Jim Doherty — Chief Development Officer Kimi Iguchi — Chief Financial […] The post Sage Therapeutics, Inc. (SAGE) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Sage Therapeutics' (SAGE) CEO Barry Greene on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.85% and 8.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

Sage Therapeutics press release (SAGE): Q4 GAAP EPS of -$2.12 beats by $0.05.Revenue of $1.6M (-99.9% Y/Y) misses by $0.17M.Ended 2021 with cash balance of $1.7 billion;…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company fearlessly leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021. “2021 was a data rich year marked by important advancements in multiple disease areas across all of our brain health franchises,” said Barry Greene, chief executive officer at Sage Therapeutics. “I’m excite

Smart Beta ETF report for EES

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.85% and 8.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

Sage Therapeutics (NASDAQ:SAGE) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$2.16 and the consensus…

Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A